Spojené štáty - angličtina - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole tablets are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of candida urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis. before prescribing fluconazole tablets for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing fluconazole tablets to amphotericin b in non-hiv infected patients have not been conducted. prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant la

Spojené štáty - angličtina - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole tablets are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of candida urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis. before prescribing fluconazole tablets for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing fluconazole tablets to amphotericin b in non-hiv infected patients have not been conducted. prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant la

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 100mg; fluconazole 100mg - capsule - 100 mg - active: fluconazole 100mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate patent blue v pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 100mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 150mg; fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 titanium dioxide active: fluconazole 150mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch sodium laurilsulfate tekprint black sw-9008 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 200mg - capsule - 200 mg - active: fluconazole 200mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 50mg; fluconazole 50mg; fluconazole 50mg - capsule - 50 mg - active: fluconazole 50mg excipient: erythrosine gelatin hydrated silica lactose monohydrate magnesium stearate patent blue v pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 50mg excipient: erythrosine gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 50mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v ponceau 4r sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Spojené štáty - angličtina - NLM (National Library of Medicine)

medvantx, inc. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 200 mg in 5 ml - azithromycin for oral suspension usp is indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae . acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae, or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin, usp should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate

Spojené štáty - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - azithromycin (unii: f94ow58y8v) (azithromycin - unii:f94ow58y8v) - azithromycin 100 mg in 5 ml - azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations . acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae . acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis or streptococcus pneumoniae . community-acquired pneumonia due to chlamydia pneumoniae , haemophilus influenzae , mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or ri

Spojené štáty - angličtina - NLM (National Library of Medicine)

apotex corp. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin 500 mg in 10 ml - azithromycin for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. as recommended dosages, durations of therapy, and applicable patient populations vary among these infections, please see dosage and administration for dosing recommendations. community-acquired pneumonia due to chlamydia pneumoniae, haemophilus influenzae, legionella pneumophila, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus, or streptococcus pneumoniae in patients who require initial intravenous therapy. pelvic inflammatory disease due to chlamydia trachomatis, neisseria gonorrhoeae, or mycoplasma hominis in patients who require initial intravenous therapy. if anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with a

Spojené štáty - angličtina - NLM (National Library of Medicine)

avpak - azithromycin anhydrous (unii: j2klz20u1m) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see dosage and administration (2)] -   acute bacterial exacerbations of chronic bronchitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . -   acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis. or streptococcus pneumoniae . -   community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae, or streptococcus pneumoniae in patients appropriate